Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenPenta vaccine formulations versus licensed meningococcal vaccines in healthy infants, toddlers, and children
2023-510465-10-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 2, single-blind trial of MenPenta SD in meningococcal disease (6 arms), sponsored by Sanofi. Planned start Mar 2025; status: authorised.
02
Drugs
MenPenta SD
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2023-510465-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510465-10-00.